Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature

REFERENCES

• Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-α. Autoimmunity. 2009;36(8):511–518.
   Google Scholar
• Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111(3):350–356.
   PubMedGoogle Scholar
• Greco A, Fusconi M, Gallo A, et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev. 2013;12(11):1033–1038.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt-koyanagi-harada syndrome. Surv Ophthalmol. 1995;39(4):265–292.
   PubMed Web of Science ®Google Scholar
• Liu XY, Peng XY, Wang S, et al. Features of optical coherence tomography for the diagnosis of Vogt-Koyanagi-Harada disease. Retina. 2016;36(11):2116–2123.
   PubMed Web of Science ®Google Scholar
• Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51(1):41–44.
   PubMed Web of Science ®Google Scholar
• O’Keefe GAD, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 2017;62(1):1–25.
   PubMed Web of Science ®Google Scholar
• Davis JL, Mittal KK, Freidlin V, et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology. 1990;97(9):1137–1142.
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Kawaguchi T, et al. Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27(2–3):87–95.
   PubMedGoogle Scholar
• Norose K, Yano A, Wang X, et al. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35(1):33–39.
   PubMed Web of Science ®Google Scholar
• Chi W, Yang P, Li B, et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007;119(5):1218–1224.
   PubMed Web of Science ®Google Scholar
• Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1996;80(11):1002–1008.
   PubMed Web of Science ®Google Scholar
• Jovic N, Nesovic M, Vranjesevic D, et al. The Vogt-Koyanagi-Harada syndrome: association with autoimmune polyglandular syndrome type 1. Postgrad Med J. 1996;72(850):495–497.
   PubMed Web of Science ®Google Scholar
• Najman-Vainer J, Levinson RD, Graves MC, et al. An association between Vogt-Koyanagi-Harada disease and Guillain-Barré syndrome. Am J Ophthalmol. 2001;131(5):615–619.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Masuda I, Ota K, et al. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy. Acta Medica Okayama. 2007;61(5):305–309.
   PubMed Web of Science ®Google Scholar
• Wilson LE, Widman D, Dikman SH, et al. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002;32(3):163–173.
   PubMed Web of Science ®Google Scholar
• Di Domizio J, Cao W. Fueling autoimmunity: type I interferon in autoimmune diseases. Expert Rev Clin Immunol. 2013;9(3):201–210.
   PubMed Web of Science ®Google Scholar
• Oppenheim Y, Ban Y, Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmun Rev. 2004;3(5):388–393.
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Disston AR, Bui DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat. 2003;10(6):467–470.
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hiraide A, Tomita N, et al. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol. 2004;39(11):1106–1109.
   PubMed Web of Science ®Google Scholar
• Papastathopoulos K, Bouzas E, Naoum G, et al. Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection. J Infect. 2006;52(2):e59–61.
   PubMedGoogle Scholar
• Touitou V, Bodaghi B, Cassoux N, et al. Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol. 2005;140(5):949–952.
   PubMed Web of Science ®Google Scholar
• Al-Muammar AM, Al-Mudhaiyan TM, Al Otaibi M, et al. Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. Int Ophthalmol. 2010;30(5):611–613.
   PubMedGoogle Scholar
• Modorati G, Matteo DF, Miserocchi E, et al. Serous retinal detachments complicating interferon-alpha and ribavirin treatment in patients with Hepatitis C. Case Rep Ophthalmol. 2011;2(1):105–110.
   PubMedGoogle Scholar
• Lim JH, Lee YN, Kim YS, et al. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol. 2011;17(1):61–65.
   PubMedGoogle Scholar
• Soma M, Hirata A, Takahashi T, et al. Relapse of Vogt-Koyanagi-Harada disease during interferon-alpha and ribavirin therapy in a case of chronic viral Hepatitis C. Case Rep Ophthalmol. 2011;2(1):5–9.
   PubMedGoogle Scholar
• Far NY, Liu DT. Probable Vogt-Koyanagi-Harada disease with initial unilateral ocular manifestation in a hepatitis C carrier. J Ophthalmic Inflamm Infect. 2012;2(4):235–237.
   PubMedGoogle Scholar
• Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21(3):613–619.
   PubMed Web of Science ®Google Scholar
• Toubi E, Gordon S, Kessel A, et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun. 2006;27(2):134–139.
   PubMed Web of Science ®Google Scholar
• Valentini G, Mantelli A, Persico M, et al. Serological and clinical markers of autoimmune disease in HCV-infected subjects with different disease conditions. Clin Exp Rheumatol. 1999;17:75–80.
   PubMed Web of Science ®Google Scholar
• Maezawa N, Yano A, Taniguchi M, et al. The role of cytotoxic T lymphocytes in the pathogenesis of Vogt-Koyanagi-Harada disease. Ophthalmologica. 1982;185(3):179–186.
   PubMed Web of Science ®Google Scholar
• Okada T, Sakamoto T, Ishibashi T, et al. Vitiligo in Vogt-Koyanagi-Harada disease: immunohistological analysis of inflammatory site. Graefes Arch Clin Exp Ophthalmol. 1996;234(6):359–363.
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Taguchi C, et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci. 2006;47(6):2547–2554.
   PubMed Web of Science ®Google Scholar
• Le Bon A, Schiavoni G, D’Agostino G, et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4):461–470.
   PubMed Web of Science ®Google Scholar
• Proietti E, Bracci L, Puzelli S, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol. 2002;169(1):375–383.
   PubMed Web of Science ®Google Scholar
• Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol. 2012;90(5):492–497.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967–972.
   PubMed Web of Science ®Google Scholar
• Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999;30(3):376–382.
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 2002;3(6):333–340.
   PubMed Web of Science ®Google Scholar
• Mori N, Imamura M, Takaki S, et al. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 2014;53(23):2689–2693.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Wallace GR, et al. Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27(1):111–136.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Abu El-Asrar AM, Bodaghi B, et al. Therapy of ocular Behçet disease. Ocul Immunol Inflamm. 2014;22(1):64–76.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–471.
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Zierhut M, et al. The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320–335.
   PubMed Web of Science ®Google Scholar
• Touitou V, Sene D, Fardeau C, et al. Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword? Int Ophthalmol. 2007;27(2–3):211–215.
   PubMedGoogle Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335–339.
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45–57.
   PubMedGoogle Scholar